Trial reportGut microbes
Gut bacteriophage dynamics during fecal microbial transplantation in subjects with metabolic syndrome.
Trial report in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Bacteriophage-mediated gut microbiota regulation: a bibliometric landscape analysis (2005-2024).Frontiers in microbiology · 2026Pooled it
- Engrafting gut bacteriophages have potential to modulate microbial metabolism in fecal microbiota transplantation.Microbiome · 2025Pooled it
- The phageome of patients with ulcerative colitis treated with donor fecal microbiota reveals markers associated with disease remission.Nature communications · 2024Trial
- Fecal microbiota transplantation alters gut phage communities in a clinical trial for obesity.Microbiome · 2024Trial
- Phage-microbe dynamics after sterile faecal filtrate transplantation in individuals with metabolic syndrome: a double-blind, randomised, placebo-controlled clinical trial assessing efficacy and safety.Nature communications · 2023Trial
- Reducing eukaryotic viruses while preserving the phageome to achieve a safer virome for fecal virome transplantation.Poultry science · 2026Article
- Beyond bacterial dysbiosis: the emerging role of gut bacteriophages in type 2 diabetes.Frontiers in cell and developmental biology · 2026Review
- Gut Microbiota Modulation in Type 2 Diabetes and Cardiometabolic Risk: A Systematic Review.Cureus · 2025Review
- Gut microbiota on cardiovascular diseases-a mini review on current evidence.Frontiers in microbiology · 2025Review
- Clinical effectiveness of fecal microbial transplantation for metabolic syndrome: Advances in clinical efficacy and multi-omics research.Current research in microbial sciences · 2025Review
- Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay.Frontiers in microbiology · 2025Review
- Bacteriophages, gut bacteria, and microbial pathways interplay in cardiometabolic health.Cell reports · 2024Review
- Targeting gut microbiota in aging-related cardiovascular dysfunction: focus on the mechanisms.Gut microbes · 2023Review
- The Next Generation Fecal Microbiota Transplantation: To Transplant Bacteria or Virome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Separate and combined effects of famine exposure and menarche age on metabolic syndrome among the elderly: a cross-sectional study in China.BMC women's health · 2023Article
- The correlation between gut microbiome and atrial fibrillation: pathophysiology and therapeutic perspectives.Military Medical Research · 2023Review
- Emerging applications of phage therapy and fecal virome transplantation for treatment of Clostridioides difficile infection: challenges and perspectives.Gut pathogens · 2023Review
- Liver-Gut-Interaction: Role of Microbiome Transplantation in the Future Treatment of Metabolic Disease.Journal of personalized medicine · 2023Article
- Characterization of the human gut virome in metabolic and autoimmune diseases.Inflammation and regeneration · 2022Review
- Drivers and determinants of strain dynamics following fecal microbiota transplantation.Nature medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Metabolic Syndrome (MetS) is a growing public health concern worldwide. Individuals with MetS have an increased risk for cardiovascular (CV) disease and type 2 diabetes (T2D). These diseases - in part preventable with the treatment of MetS - increase the chances of premature death and pose a great economic burden to health systems. A healthy gut microbiota is associated with a reduction in MetS, T2D, and CV disease. Treatment of MetS with fecal microbiota transplantation (FMT) can be effective, however, its success rate is intermediate and difficult to predict. Because bacteriophages significantly affect the microbiota membership and function, the aim of this pilot study was to explore the dynamics of the gut bacteriophage community after FMT in MetS subjects. We performed a longitudinal study of stool bacteriophages from healthy donors and MetS subjects before and after FMT treatment. Subjects were assigned to either a control group (self-stool transplant, n = 3) or a treatment group (healthy-donor-stool transplant; n-recipients = 6, n-donors = 5). Stool samples were collected over an 18-week period and bacteriophage-like particles were purified and sequenced. We found that FMT from healthy donors significantly alters the gut bacteriophage community. Subjects with better clinical outcome clustered closer to the heathy donor group, suggesting that throughout the treatment, their bacteriophage community was more similar to healthy donors. Finally, we identified bacteriophage groups that could explain these differences and we examined their prevalence in individuals from a larger cohort of MetS FMT trial.Trial information- http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2705; NTR 2705.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.